c.35G>TNM_004985.512-25245350-C-A| ISSVA entity | Allele fraction | Sources |
|---|---|---|
| GSD | 23% (targeted panel, 142/620 reads); 28% (WES, 15/55 reads) | |
| CCLA | 0.77% (Li 2023, CLA063); 29% (Sheppard 2023, nevus sebaceous) |
Bars show the reported allele-fraction range on a 0 to 50 percent axis.
Variant in the RAS-MAPK pathway. Repurposed drugs already used in the clinic for this pathway: trametinib and other MEK inhibitors.
Mentioned in 6,697 publications indexed by Europe PMC.